Paige Prostate (Paige Prostate Detect)
Save to shortlistLast reviewed Nov 11, 2026 against the sources listed on this page · How we review
At a glance
Paige Prostate is the first AI-based digital pathology product to receive FDA De Novo marketing authorization (September 2021), acting as an in vitro diagnostic that flags suspicious foci on…
- FDA:
- De Novo DEN200080
- Epic:
- Not on record
- Named users:
- 4 reported by the maker
- Published study:
- Yes, linked below
Description
Paige Prostate is the first AI-based digital pathology product to receive FDA De Novo marketing authorization (September 2021), acting as an in vitro diagnostic that flags suspicious foci on digitized prostate needle-biopsy whole-slide images. In a pivotal study of 16 pathologists and 527 slides it raised average sensitivity from 89.5% to 96.8% and cut false negatives by 70%. It is used as a 'second set of eyes' alongside the FDA-cleared FullFocus digital pathology viewer.
Quick answers
Answered only from the sourced records on this page. Questions we can't answer from the record are left out. How we review
- Is Paige Prostate (Paige Prostate Detect) FDA cleared?
- The public FDA database has one record that our team matched to Paige Prostate (Paige Prostate Detect). The most recent is De Novo DEN200080 (Paige Prostate), decided Sep 2021. Check that the cleared use matches how you plan to use it.FDA record DEN200080
- Is there published research on Paige Prostate (Paige Prostate Detect)?
- Yes, this listing links a published study. Check whether the patients and setting in the study look like yours.Read the study
Security & contracting
The maker has not reported these details yet. Ask the vendor directly during evaluation.
- Workflow stage
- Not reported
- Integrations
- Not reported
- Data inputs
- Not reported
- Deployment
- Not reported
- Signs a BAA
- Not reported
- SOC 2 report
- Not reported
- HITRUST
- Not reported
- Evidence type
- Not assessed
Readiness details are self-reported by the maker and are not checked by Clinical Intelligence Foundry. Evidence type describes the kind of study or document the listing links to; it is not a rating or endorsement. Confirm compliance documents with the vendor before purchase.
Who's using this
4 organizationsOrganizations named in public announcements or by the developer. Inclusion is not an endorsement.
Reported by the developer
Last checked Oct 31, 2026. Spot an error? Let us know through the discussion below.
Get weekly updates for Radiology
Up to 5 new items a week: new tools, FDA decisions and studies. Newest first, never ranked. Confirm by email, unsubscribe any time.
Sources
This listing links to primary sources. Follow the links below to check details directly with the developer, regulator or publication.
Website Research PaperFDA database records
- DEN200080 · De Novo · Sep 2021Paige Prostate
Matched by our team from the public FDA database; checked Nov 10, 2026.
History (2)Show
Dated events on this listing's public record, newest first.
- Sep 13, 2026
Added to CIFoundry
- Sep 21, 2021
FDA De Novo DEN200080 decision datesource
Developer
Paige AI, Inc.
Paige AI, Inc. (subsidiary of Tempus AI)
Evaluating this tool?
Get a printable packet for your committee: what the public record shows, the gaps to raise with the vendor, and the questions for this kind of tool.
Prepare evaluation packetChecklist for your role: Admin · Physician · IT · Compliance
Compare similar tools →